Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Prolifer...

Printer-friendly versionSend by emailPDF version

Name

Merck and Company

Anticipated Amount

408 663.00

Activity Type

Clinical Trial

Award Type

Contract

Date

July 8, 2012 to August 29, 2014

Award Number

005649-00001

Sponsor Award Number

MK-8669-064-13

Award Contacts

Name

Stopeck,Alison T

Title

Principal Investigator

Unit

Medicine

UA@Work is produced by University Communications

888 N. Euclid Ave., Ste. 413 (or) 
P.O. Box 210158, Tucson, AZ 85721

T 520.621.1877  F 520.626.4121

Feedback

2018 © The Arizona Board of Regents on behalf of the University of Arizona